Luventix to Showcase AI Disease Diagnostics at LD Micro Event

On October 25, 2024, Luventix Inc., based in Henderson, Nevada, announced its participation in the LD Micro Main Event XVII Conference, which will be held in Los Angeles, California from October 28-30, 2024. The company specializes in pioneering methods for disease diagnostics through the use of artificial intelligence combined with urine analysis. During the conference, CEO George Holmes and COO Dejan Nenov will engage in investment meetings and deliver a virtual presentation focusing on their innovative diagnostic approach set for October 29, 2024, at the Luxe Sunset Boulevard Hotel. The methodology developed by Luventix aims to create 'Digital Twins' of individuals' metabolic profiles, analyzing urine samples to detect abnormalities indicative of specific diseases. This advancement marks a significant shift from traditional diagnostic processes, which can be time-consuming and less efficient. By leveraging gas chromatography and advanced AI technologies, Luventix plans to enhance the accuracy and speed of disease detection, potentially transforming the health diagnostic landscape. The announcement highlights Luventix’s goal to showcase its breakthroughs in diagnostics at one of the most significant investor events, thereby enhancing the company’s visibility among investors and industry experts. It emphasizes the effectiveness and innovation behind their technology that could redefine the future of healthcare diagnostics. As the conference approaches, Luventix is engaging with various stakeholders, inviting potential investors and media representatives to learn about their pioneering work in the field of Intelligent Disease Diagnostics.